NCT04701502

Efficacy and Safety of Viusid and Asbrip in Hospitalized Patients With Mild and Moderate COVID-19

• Status: Completed
• Phase: Phase 2
• Study type: Interventional
• Enrollment: 60 (actual)
• Sponsor: Catalysis SL · Industry
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

This is a two-arm, randomized, open label, two-center, controlled study to evaluate the safety and efficacy of Viusid plus Asbrip in patients with mild and moderate symptoms of respiratory illness caused by Coronavirus 2019 infection.

Detailed description

This is a two-arm, randomized, open label, two-center, controlled study to evaluate the safety and efficacy of Viusid plus Asbrip in patients with mild and moderate symptoms of respiratory illness caused by Coronavirus 2019 infection. A total of 60 subjects will be randomized 2:1 in this study. 40 patients will be assigned to receive daily oral doses of 30 ml of Viusid and 10 ml of Asbrip every 8 hours and standard care. Other 20 patients will be assigned to receive only standard care. Treatment duration: 21 days

Conditions

• Covid19
• Respiratory Disease
• Immune System
• Immunomodulator
• Antiseptic
• Supportive Care

Interventions

Type	Name	Description
DIETARY_SUPPLEMENT	Viusid	Patients received daily doses of 30 ml of Viusid every 8 hours plus standard care for COVID-19. Viusid is administered orally. Treatment duration: 21 days
DIETARY_SUPPLEMENT	Asbrip	Patients received daily doses of 10 ml of Asbrip every 8 hours plus standard care for COVID-19. Asbrip is administered orally. Treatment duration: 21 days
DRUG	Standard Care	Standard care for COVID-19

Timeline

• Start date: 2020-11-09
• Primary completion: 2021-02-15
• Completion: 2021-02-15
• First posted: 2021-01-08
• Last updated: 2021-10-21

Locations

2 sites across 1 country: Bulgaria